Supriya Lifescience Limited (NSE:SUPRIYA)

Market Cap	73.82B +38.1%
Revenue (ttm)	8.28B +18.9%
Net Income	2.09B +11.3%
EPS	25.98 +11.3%
Shares Out	80.48M
PE Ratio	35.31
Forward PE	n/a
Dividend	1.00 (0.10%)
Ex-Dividend Date	Sep 4, 2025

Volume	721,392
Open	917.30
Previous Close	917.25
Day's Range	881.45 - 935.00
52-Week Range	545.50 - 1,085.00
Beta	0.45
Analysts	Buy
Price Target	940.00 (+4.83%)
Earnings Date	May 27, 2026

About Supriya Lifescience

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 515
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SUPRIYA

Financial Performance

In fiscal year 2026, Supriya Lifescience's revenue was 8.28 billion, an increase of 18.86% compared to the previous year's 6.96 billion. Earnings were 2.09 billion, an increase of 11.26%.

Analyst Summary

According to 2 analysts, the average rating for SUPRIYA stock is "Buy." The 12-month stock price target is ₹940.00, which is an increase of 4.83% from the latest price.

Price Target

₹940.00

(4.83% upside)

Analyst Consensus: Buy